In several studies in subjects with diabetes, GLP-1- whether administered by intravenous or subcutaneous infusion – normalized both fasting and postprandial glycemia by enhancing glucose-mediated insulin secretion, as well as by suppressing glucagon secretion [66-69]. The gene discussed is INS; the disease is diabetes mellitus.